M&As this week: Savara Pharma, Xiangxue Pharmaceuticals

23 June 2016 (Last Updated June 23rd, 2016 18:30)

Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.

Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.

Pursuant to the transaction, Savara Pharma will acquire all of Serendex Pharma's assets to add up to two new programmes in its pipeline.

Xiangxue Pharmaceuticals has announced that it will acquire a 60% stake in a Guangzhou-based biotechnology company.

Xiangxue Pharmaceuticals plans to acquire the company through stake acquisition and in the form of cash or equity.